{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$9.78 vs. cons $9.56",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$103.6B vs. cons $103.88B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Oncology & Multispecialty adjusted operating profit",
      "prediction": "BEAT",
      "answer": "pred ~$354M vs. cons $347M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BETTER",
      "answer": "guide ~$44.50 midpoint vs. cons $44.29 (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted operating-profit growth",
      "prediction": "BETTER",
      "answer": "guide ~10.5% midpoint vs. cons 10.0% (FY2027)",
      "confidence": "LOW"
    },
    {
      "kpi": "Free cash flow",
      "prediction": "UNCHANGED",
      "answer": "guide ~$4.70B midpoint vs. cons $4.70B (FY2027)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.1,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.2,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A predicted ~$0.22 Q1 EPS beat versus consensus and a ~$0.30 increase in the FY2027 guidance midpoint leave roughly $0.08 of positive out-period math, supporting modest estimate revisions and follow-through rather than a fade.",
  "day5_confidence": "MEDIUM"
}